2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy
Year: 2021
Type: article
Abstract: The worldwide spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious coronavirus disease (COVID-19) has posed a unique challenge to medical staff, patients and their families. Patients with cancer, particularly those with haematologic malignancies, have been identified to be at high risk to develop severe COVID-19. Since publication of our previous guideline on evidence-based management of COVID-19 in patients with cancer, research efforts have continued and new relevant data has come to light, maybe most importantly in the field of vaccination studies. Therefore, an update of our guideline on several clinically important topics is warranted. Here, we provide a concise update of evidence-based recommendations for rapid diagnostics, viral shedding, vaccination and therapy of COVID-19 in patients with cancer. This guideline update was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology by critically reviewing the currently available data on these topics applying evidence-based medicine criteria.
Source: European Journal of Cancer
Authors: Nicola Giesen, Rosanne Sprute, Maria Rüthrich, Yascha Khodamoradi, Sibylle C. Mellinghoff, Gernot Beutel, Catherina Lueck, Michael Koldehoff, Marcus Hentrich, Michael Sandherr, Michael von Bergwelt-Baildon, Hans-Heinrich Wolf, Hans H. Hirsch, Bernhard Wörmann, Oliver A. Cornely, Philipp Köhler, Enrico Schalk, Marie von Lilienfeld-Toal
Institutions: University Hospital Heidelberg, University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University Hospital Cologne, Jena University Hospital, Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI), Goethe University Frankfurt, University Medical Center Hamburg-Eppendorf, Medizinische Hochschule Hannover, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, Essen University Hospital, University of Duisburg-Essen, German Red Cross, LMU Klinikum, Ludwig-Maximilians-Universität München, Südharz Klinikum, University of Basel, University Hospital of Basel, Charité – Universitätsmedizin Berlin, Otto-von-Guericke-Universität Magdeburg
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,800
Funders: Amgen, Pfizer, Sanofi, Gilead Sciences, Celgene, Medpace, Deutsches Zentrum für Infektionsforschung, Cidara Therapeutics, Jazz Pharmaceuticals, Leuka, Mylan, Amplyx, Nabriva Therapeutics, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Bundesministerium für Gesundheit, Astellas Pharma, Shionogi, Ludwig-Maximilians-Universität München, Deutsche Krebshilfe, Universität zu Köln, Medac, Da Volterra, Chugai Pharmaceutical
OpenAlex ID: W3127050100